AXIM Biotechnologies Inc. will build the a new 6,000 square meters manufacturing facility at the industrial estate Stichtsekant in the city of Almere, The Netherlands.

In the next month AXIM Biotech will work with the builder and architects on drafting building plans and a detailed engineering building plan with respect to permit applications and subsequent approvals. After the final purchase of the land, AXIM Biotech will break ground on construction.

“We are extremely grateful to the government of the province of Flevoland for allowing AXIM Biotech to establish manufacturing in Almere,” said George Anastassov, chief executive officer, AXIM Biotech. “The factory plans are compliant with the highest European and International standards and will produce unique pharmaceutical and nutraceutical products, all from agricultural hemp.”

AXIM Biotechnologies is planning the state-of-the-art Almere facility to feature a clean laboratory zone, storage areas, office and technical rooms as well as manufacturing facility furnishings. AXIM’s global manufacturing hub in Almere will have the capacity to process raw materials and manufacture the company’s hemp-based pharmaceutical, nutraceutical and consumer products, which are all based on their own intellectual property. Project design and feasibility has begun and the Company is targeting the completion of construction by 2017.

“This is an exciting time for life sciences as AXIM establishes a fully ‘green’ agricultural hemp-based biotech manufacturing facility,” said Lekhram Changoer, chief technical officer. “At AXIM, the hemp manufacturing byproducts will be used and result in a net negative carbon footprint that is beneficial to the environment.”

AXIM Biotech holds exclusive rights to the world’s first patented cannabinoid release chewing gum and, with it, plans to conduct clinical trials for pain and spasticity associated with multiple sclerosis (MS) set in the EU. The company is focused upon unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. THC, CBD, CBG, CBN, etc.) and finding solutions for conditions for which there is currently no effective treatment including: MS, spasticity, pain, Parkinson’s disease, Alzheimer’s disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease.